Join Growin Stock Community!

瑩碩生技6677.TW Overview

TW StockBiotech. & Medical
(No presentation for 6677)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

瑩碩生技（6677）Overall Performance

瑩碩生技（6677）AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

瑩碩生技（6677） PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

瑩碩生技（6677）Key Information

瑩碩生技（6677）Profile

Anxo Pharmaceutical Co., Ltd., a specialty pharmaceutical company, develops, manufactures, and sells pharmaceutical products for medical professionals and patients in Taiwan and internationally. The company offers prescription and over the counter drugs in various therapeutic areas, such as cardiovascular, metabolism, CNS, diabetic, respiratory, anti-infection, dermatology, nephrology, urology, orthopedics, etc. It also offers drugs for antidiabetic/dyslipidaemic agents, cardiovascular/circulatory system, nervous system, hepatology/gastroenterology, anti-infectives/anti-viruses, hemodialysis/urinary system, respiratory system/antihistamine, analgesics, and others; and injections. The company was founded in 2003 and is headquartered in Taipei, Taiwan.

瑩碩生技（6677）FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.11
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
0.65
PB Ratio
1.05
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
37.52%
Net Margin
-3.47%
Revenue Growth (YoY)
3.36%
Profit Growth (YoY)
-3.54%
3-Year Revenue Growth
-2.33%
3-Year Profit Growth
-5.32%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.11
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
0.65
PB Ratio
1.05
Price-to-FCF
-
Gross Margin
37.52%
Net Margin
-3.47%
Revenue Growth (YoY)
3.36%
Profit Growth (YoY)
-3.54%
3-Year Revenue Growth
-2.33%
3-Year Profit Growth
-5.32%
default symbol

6677

瑩碩生技

20.95D

1.43%

(0.01)

  • When is 6677's latest earnings report released?

    The most recent financial report for 瑩碩生技 (6677) covers the period of 2025Q2 and was published on 2025/06/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating 6677's short-term business performance and financial health. For the latest updates on 6677's earnings releases, visit this page regularly.

  • What is the operating profit of 6677?

    According to the latest financial report, 瑩碩生技 (6677) reported an Operating Profit of -26.43M with an Operating Margin of -6.56% this period, representing a growth of 24.56% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is 6677's revenue growth?

    In the latest financial report, 瑩碩生技 (6677) announced revenue of 402.78M, with a Year-Over-Year growth rate of -2.92%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much cash does 6677 have?

    At the end of the period, 瑩碩生技 (6677) held Total Cash and Cash Equivalents of 314.32M, accounting for 0.15 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does 6677 go with three margins increasing?

    In the latest report, 瑩碩生技 (6677) did not achieve the “three margins increasing” benchmark, with a gross margin of 34.54%%, operating margin of -6.56%%, and net margin of -5.31%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess 6677's profit trajectory and future growth potential.

  • Is 6677's EPS continuing to grow?

    According to the past four quarterly reports, 瑩碩生技 (6677)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.36. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of 6677?

    瑩碩生技 (6677)'s Free Cash Flow (FCF) for the period is 48.25M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 24.65% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.